KBC Group’s Dr. Reddy's Laboratories RDY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$91K Buy
7,236
+689
+11% +$8.53K ﹤0.01% 1447
2026
Q2
$95K Buy
6,547
+1,054
+19% +$14.2K ﹤0.01% 1453
2026
Q1
$76K Buy
+5,493
New +$76.5K ﹤0.01% 1478
2014
Q3
– Sell
-21,465
Closed -$185K – 1328
2014
Q2
$185K Sell
21,465
-14,860
-41% -$125K ﹤0.01% 1082
2014
Q1
$319K Hold
36,325
– – 0.01% 899
2013
Q4
$298K Sell
36,325
-6,410
-15% -$50.7K ﹤0.01% 938
2013
Q3
$323K Hold
42,735
– – 0.01% 904
2013
Q2
$323K Buy
+42,735
New +$312K 0.01% 906

Other funds holding RDY

KBC Group's RDY Position: Q3 2026 in Review

KBC Group increased its Dr. Reddy's Laboratories (RDY) stake by 11% in Q3 2026, buying an estimated $8.53K and bringing the position to 7,236 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #1447.

KBC Group first reported a position in RDY in Q2 2013 and has held it in 8 quarters since. The position peaked at $323K in Q3 2013. 232 funds tracked by Wall St. Rank hold RDY as of Q3 2026.

  • KBC Group held 7,236 shares of Dr. Reddy's Laboratories worth $91K as of Q3 2026.
  • KBC Group bought 689 Dr. Reddy's Laboratories shares in Q3 2026, an estimated $8.53K.
  • Dr. Reddy's Laboratories made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1447 holding.
  • KBC Group first reported a position in Dr. Reddy's Laboratories in Q2 2013 and has held it in 8 quarters since.
  • KBC Group's Dr. Reddy's Laboratories position peaked at $323K in Q3 2013.
  • 232 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.